IHT : Las patentes son parte de la solución, no el problema
Por lo que leo en Internet, el IHT es uno de los periodicos que con mayor sensatez tratan el tema de las patentes.
There is a growing chorus of anti-patent advocates in the United States claiming the answer lies in getting rid of patents and making every innovation available to any producer, so that private companies would compete to market generic versions of every new drug or device.
Alternativas:
1) Aumentar los impuesto para poder financiar la I+D; inmediata incorporación de los resultados al dominio público.
2) Premio a las mejores innovaciones - mediante contrato con organismos publicos para su explotacion o en metalico. Incorporacion al dominio publico.
The key to the economics of patents is that rewards for large investments are great only if a firm succeeds in producing something of large value to others. This is what a publicly supported system cannot provide. Who would decide what research will lead to valuable pharmaceutical or technological developments, a civil servant or, worse, members of Congress?.
Still, there are real problems with the current system. Patent rights provide little incentive for the development of anything with a very limited market, including drugs for rare conditions..
While live-saving drugs are out of reach for some poor people in developing nations, the culprit is not patent and price: It is the abject poverty and the reluctance of rich nations to pick up the bill.
The United States, the G-7 and the United Nations all need to do more to get people in developing nations the drugs and medical devices they need to cure rampant and deadly disease. But we should not consider trying to accomplish that by upending the system that produced the drugs and devices in the first place.
There is a growing chorus of anti-patent advocates in the United States claiming the answer lies in getting rid of patents and making every innovation available to any producer, so that private companies would compete to market generic versions of every new drug or device.
Alternativas:
1) Aumentar los impuesto para poder financiar la I+D; inmediata incorporación de los resultados al dominio público.
2) Premio a las mejores innovaciones - mediante contrato con organismos publicos para su explotacion o en metalico. Incorporacion al dominio publico.
The key to the economics of patents is that rewards for large investments are great only if a firm succeeds in producing something of large value to others. This is what a publicly supported system cannot provide. Who would decide what research will lead to valuable pharmaceutical or technological developments, a civil servant or, worse, members of Congress?.
Still, there are real problems with the current system. Patent rights provide little incentive for the development of anything with a very limited market, including drugs for rare conditions..
While live-saving drugs are out of reach for some poor people in developing nations, the culprit is not patent and price: It is the abject poverty and the reluctance of rich nations to pick up the bill.
The United States, the G-7 and the United Nations all need to do more to get people in developing nations the drugs and medical devices they need to cure rampant and deadly disease. But we should not consider trying to accomplish that by upending the system that produced the drugs and devices in the first place.
0 Comments:
Publicar un comentario
<< Home